Alivus Life Sciences Ltd
ALIVUS
Company Profile
Business description
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
Contact
470, Cardinal Gracious Road
4th Floor, OIA House
Andheri (East)
MumbaiMH400 099
INDT: +91 2268297979
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
2,220
Stocks News & Analysis
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.60 | 19.70 | -0.22% |
| CAC 40 | 8,021.22 | 90.80 | -1.12% |
| DAX 40 | 24,606.64 | 352.42 | -1.41% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,083.69 | 111.66 | -1.10% |
| HKSE | 26,487.51 | 76.39 | -0.29% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 52,991.10 | 592.47 | -1.11% |
| NZX 50 Index | 13,573.93 | 6.36 | -0.05% |
| S&P 500 | 6,940.01 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,815.90 | 20.70 | -0.23% |
| SSE Composite Index | 4,113.65 | 0.35 | -0.01% |